| 000 | 01848 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250514031313.0 | ||
| 264 | 0 | _c20020507 | |
| 008 | 200205s 0 0 eng d | ||
| 022 | _a0887-6924 | ||
| 024 | 7 |
_a10.1038/sj.leu.2402407 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aManabe, A | |
| 245 | 0 | 0 |
_aAllogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. _h[electronic resource] |
| 260 |
_bLeukemia _cApr 2002 |
||
| 300 |
_a645-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aBone Marrow _xpathology |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHLA-A Antigens _ximmunology |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aKaryotyping |
| 650 | 0 | 4 |
_aLeukemia, Myelomonocytic, Chronic _xdiagnosis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethotrexate _xtherapeutic use |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 700 | 1 | _aOkamura, J | |
| 700 | 1 | _aYumura-Yagi, K | |
| 700 | 1 | _aAkiyama, Y | |
| 700 | 1 | _aSako, M | |
| 700 | 1 | _aUchiyama, H | |
| 700 | 1 | _aKojima, S | |
| 700 | 1 | _aKoike, K | |
| 700 | 1 | _aSaito, T | |
| 700 | 1 | _aNakahata, T | |
| 773 | 0 |
_tLeukemia _gvol. 16 _gno. 4 _gp. 645-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.leu.2402407 _zAvailable from publisher's website |
| 999 |
_c11862776 _d11862776 |
||